Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Free Research Reports on AVEO, CLSN, PATH and VVUS Issued by the Bedford Report

IMNN
Free Research Reports on AVEO, CLSN, PATH and VVUS Issued by the Bedford Report
http://media.marketwire.com/attachments/201211/53317_equitynewscircuit-logo-final.jpghttp://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=975851&ProfileId=051205&sourceType=1

NEW YORK, NY -- (Marketwire) -- 01/18/13 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) shares fell 6 percent on nearly ten-times the average daily volume Thursday. The company priced an offering of 6.7 million shares at $7.50 a share, which was a 7.6% discount at the close of trading Wednesday.

Find out more about AVEO Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/AVEO

Celsion Corporation (NASDAQ: CLSN) shares declined 10 percent on more than twice the average daily volume Thursday. Analysts at Brean Capital have recently downgraded the company's rating to "sell" from "buy."

Find out more about Celsion including full access to the free equity report at: www.BedfordReport.com/CLSN

NuPathe Inc. (NASDAQ: PATH) surged 15 percent on nearly four-times the average daily volume Thursday. The company's lead product candidate Zecuity has been approved by the FDA for the acute treatment of migraine with or without aura in adults.

Find out more about NuPathe including full access to the free equity report at: www.BedfordReport.com/PATH

VIVUS, Inc. (NASDAQ: VVUS) shares declined 4 percent on nearly 5 million shares traded Wednesday after analysts at Brean Capital downgraded the company's rating to "sell" from "hold." The firm stated "the competitive environment is only going to increase."

Find out more about VIVUS including full access to the free equity report at: www.BedfordReport.com/VVUS

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.

A third party, Providence Media Strategies LLC has paid Equity News Circuit four hundred and fifty dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information:

Equity News Circuit
Email Contact



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today